|
Orthologous residues
|
|
VASP (human): S157‑p, VASP (mouse): S153‑p, VASP (rat): S154‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
electrophoretic mobility shift, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'muscle, smooth'-'heart, artery'
|
|
Cellular systems studied:
primary cells
|
|
Species studied:
rat
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
PKCA (rat)
|
pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
serum
|
|
|
|
increase
|
|
|
forskolin
|
|
|
|
increase
|
|
|
8-Rp-cAMP
|
forskolin
|
|
|
inhibit treatment-induced decrease
|
|
|
SNAP
|
|
|
|
increase
|
|
|
Rp-cGMP
|
SNAP
|
|
|
inhibit treatment-induced increase
|
|
|
phorbol ester
|
|
|
|
increase
|
|
|
GF109203X
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
Go 6976
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
Go 6983
|
phorbol ester
|
|
|
inhibit treatment-induced increase
|
|
|
